{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-042647","form_type":"8-K","ticker":"RKDA","cik":"0001469443","company_name":"Arcadia Biosciences, Inc.","filed_at":"2025-03-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.716927+00:00","generated_at":"2026-05-24T10:04:52.054339+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Arcadia Biosciences Q4 revenue +56% YoY to $1.2M; net loss widens; Roosevelt deal on track","bullets":["Q4 total revenues $1.216M (+56% YoY); FY2024 revenues $5.045M (+13% YoY).","Net loss attributable to common stockholders Q4 $4.064M ($2.98/share) vs $2.853M in Q4 2023.","Full-year net loss improved to $7.038M ($3.17/share) from $13.981M in 2023.","Zola coconut water revenue up 124% in Q4 and 46% for full year.","Pending merger with Roosevelt Resources; post-close owners get ~90% of shares, Arcadia holders ~10%."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-042647","json":"https://secwatch.observer/filing/0000950170-25-042647.json","markdown":"https://secwatch.observer/filing/0000950170-25-042647.md","text":"https://secwatch.observer/filing/0000950170-25-042647.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1469443/000095017025042647/0000950170-25-042647-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1469443/000095017025042647/rkda-20250320.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T10:04:52.054339+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}